August 26, 2016
June 21, 2016
March 22, 2016
January 22, 2016
March 3, 2015
October 16, 2014
August 22, 2014
June 18, 2014
May 15, 2014
March 26, 2014
November 6, 2013
October 11, 2013
August 29, 2013
June 13, 2013
March 28, 2013
February 25, 2013
How can benefit providers collaborate with drug manufacturers to ensure maximum value for drug spending? Read the answer
Download a PDF of the 2016 Top 50 DC Plans report
CPP changes do little to ensure appropriate income for future retireesFred Vettese
Download the latest issue now
Freedom of choice may be coming to an end in drug plans
Kenneth MacDonald
Solving the benefits plan design equation for 2017
Mike Sullivan
How foundations can leverage investment portfolios to further their cause
Neil Davidge
Tackling the challenges of benefits provision for employees over age 65
Kim Siddall
When is it OK to say no at work?
Karley Middleton
How employee health trusts can help manage ballooning benefits costs
Susan Deller
B.C. government doing little to solicit feedback on CPP enhancement
Greg Hurst
How to manage the long-term obligations of a DB pension promise
Gavin Benjamin
Private debt a good option for bond refugees
Janet Rabovsky
Time for plan sponsors to embrace digital innovations in health care
Brian Lindenberg
How to avoid legal liability for benefits communications
Claude Marchessault
The evolution of asset allocation: Using alternatives to overcome challenges
Jonathan Jacob
The volatility of correlation and its impact on portfolio design
Martin Leclair and Lewis Powell
Despite complexities, expanded CPP the right call
Fred Vettese
The pros and cons of employee share purchase plans
Scott Anderson
6 tips for engaging employees in their health
Linda Lewis Daly
Latest
Post a job
Vice-President, Investment Policy and Risk Management
DC Investment Forum More Info
